Roobol M - Search Results

1

Real-time Watchful Surveillance Looks Like Active Waiting.

Bangma C, Roobol M. Bangma C, et al. Among authors: roobol m. Eur Urol. 2017 Dec;72(6):908-909. doi: 10.1016/j.eururo.2017.08.003. Epub 2017 Aug 17. Eur Urol. 2017. PMID: 28822584 No abstract available.

2

A more advanced clinical stage is positively correlated with an increased prostate cancer detection rate.

Roobol MJ, Kranse R, van der Cruijsen IW, Schröder FH. Roobol MJ, et al. Urology. 2002 Jan;59(1):91-6. doi: 10.1016/s0090-4295(01)01479-0. Urology. 2002. PMID: 11796288 Clinical Trial.

3

Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.

Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Raaijmakers R, et al. Urology. 2002 Nov;60(5):826-30. doi: 10.1016/s0090-4295(02)01958-1. Urology. 2002. PMID: 12429309

4

Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.

Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, Schröder FH. Raaijmakers R, et al. Urology. 2004 Feb;63(2):316-20. doi: 10.1016/j.urology.2003.09.028. Urology. 2004. PMID: 14972481

5

Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness.

Raaijmakers R, Blijenberg BG, Finlay JA, Rittenhouse HG, Wildhagen MF, Roobol MJ, Schröder FH. Raaijmakers R, et al. J Urol. 2004 Jun;171(6 Pt 1):2245-9. doi: 10.1097/01.ju.0000127731.56103.50. J Urol. 2004. PMID: 15126795

6

Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).

Roobol MJ, Roobol DW, Schröder FH. Roobol MJ, et al. Urology. 2005 Feb;65(2):343-6. doi: 10.1016/j.urology.2004.09.046. Urology. 2005. PMID: 15708050

7

Rotterdam randomized pilot studies of screening for prostate cancer--an overview after 10 years.

Schröder FH, Roobol MJ, Damhuis RA, de Koning HJ, Blijenberg BG, Van der Kwast TH, Kirkels WJ, Bangma CH. Schröder FH, et al. Among authors: roobol mj. J Natl Cancer Inst. 2005 May 4;97(9):696. doi: 10.1093/jnci/dji121. J Natl Cancer Inst. 2005. PMID: 15870441 No abstract available.

8

Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.

van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH, Schröder FH. van der Cruijsen-Koeter IW, et al. J Urol. 2005 Jul;174(1):121-5. doi: 10.1097/01.ju.0000162061.40533.0f. J Urol. 2005. PMID: 15947595 Clinical Trial.

9

Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.

Schröder FH, Roobol MJ, Boevé ER, de Mutsert R, Zuijdgeest-van Leeuwen SD, Kersten I, Wildhagen MF, van Helvoort A. Schröder FH, et al. Eur Urol. 2005 Dec;48(6):922-30; discussion 930-1. doi: 10.1016/j.eururo.2005.08.005. Epub 2005 Oct 17. Eur Urol. 2005. PMID: 16263208 Clinical Trial.

10

Tumour features in the control and screening arm of a randomized trial of prostate cancer.

Postma R, van Leenders AG, Roobol MJ, Schröder FH, van der Kwast TH. Postma R, et al. Eur Urol. 2006 Jul;50(1):70-5. doi: 10.1016/j.eururo.2005.11.005. Epub 2005 Dec 19. Eur Urol. 2006. PMID: 16434136 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

510 results

Search Page

Filters